Kamada (KMDA) - Total Liabilities
Based on the latest financial reports, Kamada (KMDA) has total liabilities worth ILA111.98 Million ILA (≈ $300.21K USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore KMDA cash flow metrics to assess how effectively this company generates cash.
Kamada - Total Liabilities Trend (2006–2024)
This chart illustrates how Kamada's total liabilities have evolved over time, based on quarterly financial data. Check financial resilience of Kamada to evaluate the company's liquid asset resilience ratio.
Kamada Competitors by Total Liabilities
The table below lists competitors of Kamada ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Bhagiradha Chemicals & Industries Limited
NSE:BHAGCHEM
|
India | Rs3.50 Billion |
|
DB Financial Investment Co Ltd
KO:016610
|
Korea | ₩11.51 Trillion |
|
Aarti Drugs Limited
NSE:AARTIDRUGS
|
India | Rs11.44 Billion |
|
Jiangsu Yuxing Film Tech
SHE:300305
|
China | CN¥1.38 Billion |
|
Chongqing Sifang New Material Co. Ltd.
SHG:605122
|
China | CN¥1.72 Billion |
|
Shivalik Bimetal Controls Limited
NSE:SBCL
|
India | Rs1.34 Billion |
|
Thessaloniki Port Authority SA
AT:OLTH
|
Greece | €76.05 Million |
|
Sinomach General Machinery Science Technology Co Ltd
SHG:600444
|
China | CN¥760.72 Million |
Liability Composition Analysis (2006–2024)
This chart breaks down Kamada's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see KMDA market cap overview.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 4.03 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.42 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.30 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Kamada's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Kamada (2006–2024)
The table below shows the annual total liabilities of Kamada from 2006 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | ILA112.79 Million ≈ $302.39K |
+1.72% |
| 2023-12-31 | ILA110.89 Million ≈ $297.28K |
-24.24% |
| 2022-12-31 | ILA146.36 Million ≈ $392.38K |
+3.18% |
| 2021-12-31 | ILA141.84 Million ≈ $380.28K |
+342.89% |
| 2020-12-31 | ILA32.03 Million ≈ $85.86K |
-16.77% |
| 2019-12-31 | ILA38.48 Million ≈ $103.16K |
+49.49% |
| 2018-12-31 | ILA25.74 Million ≈ $69.01K |
-21.09% |
| 2017-12-31 | ILA32.62 Million ≈ $87.45K |
-1.02% |
| 2016-12-31 | ILA32.95 Million ≈ $88.35K |
+11.76% |
| 2015-12-31 | ILA29.48 Million ≈ $79.05K |
-23.66% |
| 2014-12-31 | ILA38.62 Million ≈ $103.55K |
-21.83% |
| 2013-12-31 | ILA49.41 Million ≈ $132.46K |
-18.63% |
| 2012-12-31 | ILA60.72 Million ≈ $162.79K |
-3.27% |
| 2011-12-31 | ILA62.78 Million ≈ $168.30K |
-3.47% |
| 2010-12-31 | ILA65.03 Million ≈ $174.36K |
+98.51% |
| 2009-12-31 | ILA32.76 Million ≈ $87.83K |
+11.36% |
| 2008-12-31 | ILA29.42 Million ≈ $78.87K |
-48.56% |
| 2007-12-31 | ILA57.19 Million ≈ $153.32K |
+33.60% |
| 2006-12-31 | ILA42.80 Million ≈ $114.76K |
-- |
About Kamada
Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its products include KAMRAB/KEDRAB indicated as prophylaxis of rabies; CYTOGAM for prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmuniza… Read more